Prospective evaluation of EBUS-TBNA specimens for programmed death-ligand 1 expression in non-small cell lung cancer patients: a pilot study-Reference-Cited by-同舟云学术

Prospective evaluation of EBUS-TBNA specimens for programmed death-ligand 1 expression in non-small cell lung cancer patients: a pilot study

Published:2021-08-31 Issue: Volume: Page:e20200584
ISSN:1806-3756
Container-title:Jornal Brasileiro de Pneumologia
language:en
Short-container-title:J Bras Pneumol.

Author:

Guarize1 Juliana¹^ORCID,Guerini Rocco2 Elena²^ORCID,de Marinis3 Filippo³^ORCID,Sedda4 Giulia⁴^ORCID,Bertolaccini4 Luca⁴^ORCID,Maria Donghi1 Stefano¹^ORCID,Casiraghi4 Monica⁴^ORCID,Di Tonno2 Clementina²^ORCID,Barberis2 Massimo²^ORCID,Spaggiari4,5 Lorenzo⁵^ORCID

Affiliation:

1. 1. Pneumologia Interventistica, Divisione di Chirurgia Toracica, Istituto Europeo di Oncologia – IEO – Istituto di Ricovero e Cura a Carattere Scientifico – IRCCS – Milano, Italia.

2. 2. Divisione di Anatomia Patologica, Istituto Europeo di Oncologia – IEO – Istituto di Ricovero e Cura a Carattere Scientifico – IRCCS – Milano, Italia.

3. 3. Divisione di Oncologia Toracica, Istituto Europeo di Oncologia – IEO – Istituto di Ricovero e Cura a Carattere Scientifico – IRCCS – Milano, Italia.

4. 4. Divisione di Chirurgia Toracica, Istituto Europeo di Oncologia – IEO – Istituto di Ricovero e Cura a Carattere Scientifico – IRCCS – Milano, Italia.

5. 4. Divisione di Chirurgia Toracica, Istituto Europeo di Oncologia – IEO – Istituto di Ricovero e Cura a Carattere Scientifico – IRCCS – Milano, Italia. 5. Dipartimento di Oncologia ed Emato-Oncologia, Università degli Studi di Milano, Milano, Italia.

Abstract

Objective: EBUS-TBNA cytological sampling is routinely performed for pathological diagnosis, mediastinal staging, and molecular testing in lung cancer patients. EBUS-TBNA samples are not formally accepted for testing programmed death-ligand 1 (PD-L1) expression. The objective of the study was to compare the feasibility, reproducibility, and accuracy of PD-L1 expression assessment in cytological specimens and histological samples. Methods: We prospectively collected histological (transbronchial forceps biopsy) and cytological (EBUS-TBNA) samples from peribronchial neoplastic lesions during an endoscopic procedure at the same target lesion for the pathological diagnosis and molecular assessment of stage IV non-small cell lung cancer (NSCLC). Results: Fifteen patients underwent the procedure. Adequate cytological samples (at least 100 neoplastic cells) were obtained in 12 cases (92.3%). Assessment of PD-L1 expression was similar between histological and cytological samples (agreement rate = 92%). Sensitivity and diagnostic accuracy of EBUS-TBNA cytological specimens were 88.9% and 100%, respectively. Conclusions: The evaluation of PD-L1 expression in EBUS-TBNA cytological specimens is feasible and presents good reproducibility when compared with routine histological samples. EBUS-TBNA cytological samples could be used for the assessment of PD-L1 expression in patients with NSCLC as a minimally invasive approach in stage IV NSCLC cancer patients.

Publisher

Sociedade Brasileira de Pneumologia e Tisiologia

Reference26 articles.

1. 1. World Health Organization [homepage on the Internet]. Geneve: WHO [cited 2020 Nov 1]. Health topics: Cancer. Available from: https://www.who.int/health-topics/cancer

2. 2. Reckamp KL, editor. Lung cancer: Treatment and Research. London: Springer; 2016. https://doi.org/10.1007/978-3-319-40389-2

3. 3. Spaggiari L, Casiraghi M, Guarize J, Brambilla D, Petrella F, Maisonneuve P, et al. Outcome of Patients With pN2 “Potentially Resectable” Nonsmall Cell Lung Cancer Who Underwent Surgery After Induction Chemotherapy. Semin Thorac Cardiovasc Surg. 2016;28(2):593-602. https://doi.org/10.1053/j.semtcvs.2015.12.001

4. 4. Yuan M, Huang LL, Chen JH, Wu J, Xu Q. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. 2019;4:61. https://doi.org/10.1038/s41392-019-0099-9

5. 5. Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018;142(3):321-346. https://doi.org/10.5858/arpa.2017-0388-CP

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A review of diagnostic bronchoscopy;Minerva Respiratory Medicine;2024-07

2. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA): revolutionizing the landscape of lung disease diagnostics;Journal of Medical Ultrasonics;2023-12-19

3. Diagnostic Performance and Cell Count of EBUS–TBNA Needle Gauges: A Prospective Trial;Journal of Clinical Medicine;2023-06-13

4. In EBUS Signo Vinces: New Indications in Thoracic Oncology for Mediastinal Lymph Node Staging Using Endobronchial Ultrasound;Frontiers in Oncology;2022-07-08

5. Effector Memory T Cells and CD45RO+ Regulatory T Cells in Metastatic vs. Non-Metastatic Lymph Nodes in Lung Cancer Patients;Frontiers in Immunology;2022-05-02